Patent: 10,130,632
✉ Email this page to a colleague
Summary for Patent: 10,130,632
| Title: | Methods for treating renal disease |
| Abstract: | The invention features methods for treating or reducing the likelihood of developing a renal disease by administering to a subject in need thereof an agent that decreases expression of a pathogenic APOL1. The agents of the method target various signaling pathways and decrease the level of the pathogenic APOL1 polypeptide. |
| Inventor(s): | Friedman; David J. (Boston, MA), Pollak; Martin R. (Boston, MA) |
| Assignee: | Beth Israel Deaconess Medical Center, Inc. (Boston, MA) |
| Application Number: | 14/646,055 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,130,632
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Pharmacia & Upjohn Company Llc | ATGAM | lymphocyte immune globulin, anti-thymocyte globulin (equine) | Injection | 103676 | 12/04/1996 | ⤷ Try a Trial | 2039-02-26 |
| Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2039-02-26 |
| Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2039-02-26 |
| Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2039-02-26 |
| Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2039-02-26 |
| Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2039-02-26 |
| Immunex Corporation | ENBREL MINI | etanercept | Injection | 103795 | 09/14/2017 | ⤷ Try a Trial | 2039-02-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
